Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Receivables (2024 - 2025)

Historic Change in Receivables for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Q3 2025 value amounting to -$3.0 million.

  • Day One Biopharmaceuticals' Change in Receivables fell 57392.29% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 797.01%. This contributed to the annual value of $13.9 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Change in Receivables of -$3.0 million as of Q3 2025, which was down 57392.29% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Change in Receivables peaked at $9.1 million during Q2 2024, and registered a low of -$3.0 million during Q3 2025.